Exhibit 2.3

 

AMENDED AND RESTATED AMENDMENT TO THE MERGER AND SHARE EXCHANGE AGREEMENT

 

This Second Amended and Restated Amendment to the Merger and Share Exchange Agreement, dated as of August 13, 2026 (this “Amendment”), by and among Zoar Limited (formerly known as “Dr Ashleys Limited”), a Cayman Islands exempted company limited by shares (“PubCo”), Impact BioMedical, Inc., a Nevada corporation (“Impact”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation (“Merger Sub”), Zoar Labs Limited (formerly known as “Dr Ashleys Bio Labs Limited”), a Cayman Islands exempted company limited by shares (“Zoar Labs”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), a Latvian national, solely in his capacity as the sole shareholder of the Company (as defined in the Initial Merger Agreement (as defined below)) (“Dr Ashleys Shareholder”). Capitalized terms not otherwise defined in this Amendment shall have the meaning given to them in the Initial Merger Agreement (as defined below).

 

W I T N E S S E T H:

 

WHEREAS, PubCo, Zoar Labs, Impact, Merger Sub, and Zoar Shareholder are parties (the “Parties”) to the Merger and Share Exchange Agreement dated as of June 21, 2025 (the “Initial Merger Agreement”);

 

WHEREAS, the parties has entered into an amended and restated amendment to the Initial Merger Agreement, dated June 30, 2026 (the “Amended and Restated Amendment to the Merger and Share Exchange Agreement”);

 

WHEREAS, in accordance with the terms of Section 14.2 of the Initial Merger Agreement, the Parties desire to enter into this Amendment (together with the Initial Merger Agreement, the Amended and Restated Amendment to the Merger and Share Exchange Agreement, the “Merger Agreement”) to amend the Merger Agreement further as set forth herein to modify certain terms and conditions of the Merger Agreement.

 

NOW, THEREFORE, in consideration of the foregoing and the respective covenants and agreements set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

SECTION 1. AMENDMENT TO THE MERGER AGREEMENT

 

1.1. The definition of “Company Share Consideration” under Section 1.1(a) of the Merger Agreement shall be deleted in its entirety and replaced as follows:

 

“Company Share Consideration” means 167,976,000 shares of PubCo Ordinary Shares, representing 93.32% of the total issued and outstanding PubCo Ordinary Shares at the Closing.”

 

1.2. The following definition shall be inserted immediately after the definition of “Dr Ashleys Shareholder” in Section 1.1(b) of the Merger Agreement.

 

DSS Shares Third Batch Section 3.2(d)

 

1.3. Section 3.2(d) of the Amended and Restated Merger Agreement shall be deleted in its entirety and replaced as follows:

 

“(d) PubCo shall issue to Frank D. Heuszel, the Chief Executive Officer of Impact, a total of 22,000 shares of PubCo Ordinary Shares (“Compensation Shares”), and to DSS, Inc., 53,000 PubCo Ordinary Shares (the “DSS Shares First Batch”), 75,000 PubCo Ordinary Shares (the “DSS Shares Second Batch”), 100,000 PubCo Ordinary Shares (the “DSS Shares Third Batch,” together with the “DSS Shares First Batch” and the “DSS Shares Second Batch,” the “DSS Shares”) at the Closing. Subject to the effectiveness of the Registration Statement, upon issuance, such Compensation Shares and DSS Shares shall be registered and freely tradable by the respective holder(s) under the Securities Act, subject only to any restrictions imposed by any applicable laws or regulations.”

 

 

 

 

1.4. Section 13.1(b) of the Merger Agreement shall be deleted in its entirety and replaced as follows:

 

“(b) by either Impact, PubCo, Dr Ashleys Shareholder, or the Company if the Contemplated Transactions shall not have been consummated by November 20, 2026 (the “End Date”) which may be extended with the mutual consent of Impact, PubCo, Dr Ashleys Shareholder and the Company; provided, however, that the right to terminate this Agreement under this Section 13.1(b) shall not be available if action or failure to act of such Party or such Party’s Subsidiaries has been a principal cause of the failure of the Contemplated Transactions to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement;”

 

SECTION 2. GENERAL PROVISION

 

2.1. Miscellaneous. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Amendment may be executed and delivered by facsimile or PDF transmission. The terms, agreements and provisions of Section 14 of the Initial Merger Agreement shall apply to this Amendment, as applicable.

 

2.2 Merger Agreement in Effect. Except as specifically and explicitly provided for in this Amendment, the Initial Merger Agreement shall remain unmodified and in full force and effect.

 

[Signature Page Follows]

 

 

 

 

WHEREOF, the Parties have caused this Amendment to be executed as of the date first above written.

 

IMPACT BIOMEDICAL INC.
     
By:    
     
Name: Frank D. Heuszel  
     
Title: Chief Executive Officer  

 

 

 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date first above written.

 

ZOAR Limited  
     
By:    
     
Name: Daphne Y. Huang  
     
Title: Chief Executive Officer  

 

 

 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date first above written.

 

ZOAR LABS LImited  
     
By:    
     
Name: Daphne Y. Huang  
     
Title: Chief Executive Officer  

 

 

 

 

WHEREOF, the Parties have caused this Amendment to be executed as of the date first above written.

 

DR ASHLEYS NEVADA SUB, INC.  
     
By:    
     
Name: Daphne Y. Huang  
     
Title: Chief Executive Officer  

 

 

 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the date first above written.

 

Dr. Ashley SHAREHOLDER  
     
By:    
     
Name: Kanans Visvanats